NCT05304065 Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth
| NCT ID | NCT05304065 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of California, Los Angeles |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2022-10-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 1,600 participants in total. It began in 2022-10-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized comparative effectiveness trial will compare two evidence-based approaches to emergency care for youth ages 13-24 who present to the Emergency Department (ED) with suicidal ideation or behavior. Outcomes will be monitored at baseline and at 3, 6 \& 12 month follow-up assessments.
Eligibility Criteria
Inclusion Criteria: * age 13-24; * past-week suicidal behavior or ideation with plan or intent Exclusion Criteria: * symptoms or illness that precludes informed consent or engagement in study procedures (e.g., active psychosis; drug dependence, no locator information); * youth not fluent in English * parent not fluent in English or Spanish.
Contact & Investigator
Joan R Asarnow, PhD
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT05304065 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 24 Years, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05304065 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05304065 currently recruiting?
Yes, NCT05304065 is actively recruiting participants. Contact the research team at lzullo@mednet.ucla.edu for enrollment information.
Where is the NCT05304065 trial being conducted?
This trial is being conducted at Los Angeles, United States, Sylmar, United States, Durham, United States, Providence, United States and 1 additional location.
Who is sponsoring the NCT05304065 clinical trial?
NCT05304065 is sponsored by University of California, Los Angeles. The principal investigator is Joan R Asarnow, PhD at University of California, Los Angeles. The trial plans to enroll 1,600 participants.